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Pharmacoeconomics/Outcomes
533. The cost of treating cancer patients with antineoplastic
medications during inpatient hospital admission Alexandra Foster,
Pharm.D. Candidate1, David Reeves, Pharm.D., BCOP2; (1)
College of Pharmacy and Health Sciences, Butler University (2)
St. Vincent Indianapolis Hospital and College of Pharmacy and
Health Sciences, Butler University
PURPOSE: Cancer treatment represents a substantial portion of
health care costs and is projected to increase by twenty-seven per-
cent from 2010 to 2020, with total costs reaching 158 billion dol-
lars per year. Due to these projections, it is imperative for
institutions to implement cost saving strategies, as well as maxi-
mize reimbursement. The objective of this study is to evaluate the
cost and necessity of providing chemotherapy regimens in the
inpatient setting and explore the savings associated with imple-
mentation of a policy defining the appropriate indications for the
use of inpatient chemotherapy.
METHODS: A retrospective chart review of adult patients receiv-
ing inpatient chemotherapy during January, April, July, and
October of 2010, 2012, and 2014 at St. Vincent Hospital in Indi-
anapolis is in progress. Demographic data, chemotherapy regi-
mens (cycle number, dosing, schedule, agents, and routes of
administration), prior adverse effects, reasons for inpatient
chemotherapy, and cost of chemotherapy regimens (average
wholesale price) are being collected. Necessity of inpatient
chemotherapy will be determined based on adherence to the avail-
able guidelines for inpatient chemotherapy. Institutional review
board approval was received on August 27, 2013.
RESULTS: Records of 415 patients receiving chemotherapy dur-
ing ten of the twelve intended months have been retrospectively
reviewed. Data collection for July and October 2012 are currently
in progress. Preliminary results indicate the annualized number of
patients receiving chemotherapy in the inpatient setting decreased
from 579 patients in 2010 to 381 patients in 2014, while the annu-
alized number of patients admitted specifically for chemotherapy
decreased from 327 patients in 2010 to 189 patients in 2014.
Financial and statistical analysis will be conducted upon comple-
tion of data collection.
CONCLUSION: Preliminary data suggests the number of
patients receiving inpatient chemotherapy and the number of
patients admitted specifically for chemotherapy decreased after
implementation of a policy in 2014 regarding appropriate inpa-
tient chemotherapy use.
534. A cost-savings analysis of a pharmacy internship program in a
hospital inpatient setting Lana Al-Omar, Pharm.D. Candidate,
Daniel Galipeau, Pharm.D. Candidate, Kristi Smith, Pharm.D.
Candidate, Michelle Sugden, Pharm.D. Candidate, Kristi Bronkan,
Pharm.D., BCPS, Corrie Vasilopoulos, Pharm.D., BCPS; Denver
Health Medical Center
PURPOSE: Pharmacy internship programs provide the opportu-
nity for pharmacy students to work and learn in a pharmacy
practice setting, however, there is scarce published data to
demonstrate the value of a pharmacy internship program to
either the pharmacy student or the institution. This study is the
first in a series of studies to assess the overall benefit of pharmacy
internship programs, specifically in the hospital inpatient setting.
The goal of this study is to assess the financial benefit of an inpa-
tient pharmacy internship program involving both clinical and
operational roles.
METHODS: The financial value of clinical services provided by
interns was calculated using intervention data from August 2013
to April 2015. The savings from interns performing clinical work
as compared to pharmacists were determined using the total time
spent on interventions and comparing the midpoint hourly wage
for interns and pharmacists. The savings from operational ser-
vices provided by interns was calculated using total hours of
intern operational work and comparing the midpoint hourly wage
for interns and pharmacy technicians.
RESULTS: The overall value of clinical services provided by
interns was $206,230 annually. The cost difference between
interns providing clinical services as compared to pharmacists
was $13,960 annually. The cost savings associated with interns
providing operational services was $11,440 annually. Results at
this time are undergoing final analysis to compile graphical data.
CONCLUSION: There is a significant financial benefit to a hos-
pital institution for supporting a pharmacy internship program.
This financial benefit should reassure hospitals that developing,
promoting and sustaining a pharmacy internship program pro-
vides value to the organization. Further research is needed to elu-
cidate the benefits of a pharmacy internship program to
pharmacy students and determine what aspects of a pharmacy
internship program are most beneficial to pharmacy students.
Pharmacogenomics/Pharmacogenetics
537. Effects of CYP2D6 genetic polymorphisms on the
pharmacokinetics of tramadol and its active metabolite Hye-Jin Lim,
B.S., Dong-Hyun Kim, B.S., Young-Hoon Kim, B.S., Se-Hyung Kim,
Ph.D.Candidate, Ji-Yeong Byeon, B.S., Seok-Yong Lee, Ph.D.; School
of Pharmacy, Sungkyunkwan University, Suwon, South Korea
PURPOSE: Tramadol is a synthetic l-receptor agonist used for
the relief of moderate to severe acute and chronic pain. Tramadol
is mainly to O-demethyltramadol (ODT) metabolized in the liver.
Also tramadol itself possesses serotonin and norepinephrine re-
uptake blocking activity. CYP2D6 is responsible for the metabo-
lism of approximately 25% of clinically used drugs and especially
CYP2D6*10 allele is accounted for 50% of CYP2D6 allele in
Asian. We investigated the effects of CYP2D6*10 allele on the
pharmacokinetics of tramadol and its active metabolite.
METHODS: Thirty healthy Korean volunteers with CYP2D6*wt/
*wt (*wt = *1 or *2, n = 10), CYP2D6*wt/*10 (n = 10) and
CYP2D6*10/*10 (n = 10) were selected for this study. Each volun-
teer received a single oral dose of 100 mg tramadol after overnight
fasting. Blood samples were collected up to 30 hour after drug
intake, and plasma concentrations of tramadol and its metabolite
were determined by using LC-MS/MS analytical system.
RESULTS: AUCinf of tramadol in CYP2D6*10/*10 group was
higher than those in CYP2D6*wt/*wt genotype group;
3237.3  765.7 ng*hour/mL and 2146.4  407.2 ng*hour /mL
(p < 0.001). But Cmax tramadol was not significantly different
among three different groups. In terms of O-demethyltramadol
(ODT), AUCinf in CYP2D6*10/*10 group was lower than those
in CYP2D6*wt/*wt genotype group; 882.7  274.0 ng*hour/mL
and 1173.9  165.9 ng*hour/mL (p < 0.001).
CONCLUSIONS: In conclusion, CYP2D6*10 allele has signifi-
cant effects on the pharmacokinetics of tramadol and its active
metabolite.
538. Effects of CYP2C9*13 allele on the pharmacokinetics of
Irbesartan Hye-Jin Lim, B.S., Dong-Hyun Kim, B.S., Ji-Yeong
Byeon, B.S., Young-Hoon Kim, B.S., Se-Hyung Kim, B.S. , Ph.D.
Candidate; School of Pharmacy, Sungkyunkwan University,
Suwon, South Korea
PURPOSE: Irbesartan is an angiotensin II antagonist that selec-
tively blocks the binding of angiotensin II to the AT1 receptor,
and is used for the treatment of hypertension, as well as diabetic
nephropathy with an elevated serum creatinine and proteinuria in
patients with type 2 diabetes and hypertension. Irbesartan is
metabolized by polymorphic CYP2C9 to inactive metabolite.
CYP2C9*13 allele show impaired activity towards a number of
substrates both in vitro and in vivo. Unlike CYP2C9*3, which has
been extensively studied in humans, clinical studies of CYP2C9*13
have been limited by the difficulty in finding subjects carrying this
low-frequency allele. We evaluated the effect of CYP2C9*13 allele
on the pharmacokinetics of irbesartan in healthy volunteers.
METHODS: In this study, we enrolled 1907 healthy Korean sub-
jects and divided into four different groups according to CYP2C9
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